Investors & media
Pure Biologics is a Polish biopharmaceutical company operating in the area of modern biological drugs. On the market since 2010, it was first in Poland to focus on developing new and innovative therapeutic molecules, not simply generic or biosimilar, based on antibodies and aptamers to be used in immuno-oncology and rare diseases applications.
In 2018, Pure Biologics entered the NewConnect market , and in 2020 transferred to the Main Market of the Warsaw Stock Exchange (as PURE).
Our team combines the recruitment of talent from renowned research groups, know-how acquired from years of activity, and an effective operating model, to drive the evolution of our own internal research projects, belonging to the most promising sectors of pharmaceutics.
Sources of funding for our therapeutic portfolio include grants from the European Union, complemented with revenue from contracted research delivered for pharmaceutical and biotechnology companies, as well as the capital invested by our company shareholders. The long-term strategy includes the partial reinvestment of profits from commercialization of our portfolio into our R&D activities and further development of the research program.
|Shareholder||% shares||% votes|
|TFI Allianz Polska S.A.||10,09||10,09|
Calendar of events and reports
RAPORT BIEŻĄCY ESPI 16/2023 – ZAWARCIE TERM SHEET DOTYCZĄCEGO WARUNKÓW UDZIELENIA FINANSOWANIA SPÓŁCE ORAZ ZASAD WSPÓŁPRACY W ZWIĄZKU Z UDZIELONYM FINANSOWANIEM. ROZPOCZĘCIE NEGOCJACJI.
RAPORT BIEŻĄCY ESPI 15/2023 – PODPISANIE UMOWY Z ABM O DOFINANSOWANIE KOLEJNYCH ETAPÓW PROJEKTU PB003 PURE ACTIVATOR
RAPORT BIEŻĄCY ESPI 14/2023 – ROZPOCZĘCIE PROCESU PRZEGLĄDU OPCJI STRATEGICZNYCH
General meetings (PL)
Corporate governance (PL)
Memoranda and prospectuses (PL)
Documents prepared in connection with the application for the introduction of financial instruments to trading conducted by the Warsaw Stock Exchange S.A.
Contact for investors
Director of the Company Office
Investor Relations Representative
Address for submitting notifications
According to Art. 19 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR)